Topic: inflammatory bowel disease
Paul-Peter Tak joins Kintai Therapeutics as it steers its “precision enteric medicines” toward the clinic, with the first trials slated to start in 2020.
Fe3 Medical is moving forward with its wearable patch that uses electrical current to deliver iron directly through the skin.
Synlogic has recruited a new chief scientific officer: Scott Plevy, M.D., who headed up gastroenterology and interleukin-23 research at Janssen.
BiomX raised $32 million for preclinical development of its customized phage cocktail therapies aimed at eradicating the bacteria behind IBD and acne.
Vedanta Biosciences will advance its pipeline of microbiome-derived drugs, including a handful of assets currently in midstage trials.
Vedanta’s pact with J&J on microbiome therapies has moved to the clinical stage, triggering a $12 million milestone payment.
Fierce 15 winner Jnana Therapeutics has installed co-founder Joanne Kotz, Ph.D., as its new CEO. She has served as president since December 2017.
Scientists at Vanderbilt University found that a glutaminase inhibitor improved the anticancer activity of CAR-T cells.
Some microRNAs could serve as prognostic markers of Crohn's and open the possibility of developing personalized therapies.
Arena Pharma says cannabinoid receptor-targeting olorinab could help treat the pain associated with Crohn’s disease.